Evidence map›Paper›PMID 41219962›Full record

ArticleGlobalization and health2025

Constructing and contesting industry's role in multistakeholder governance: a qualitative analysis of responses to WHO consultations.

Amber van den Akker, Xinmei Sun, Britta K Matthes, Kathrin Lauber, Anna B Gilmore

Abstract read
In one paragraph

Article in Globalization and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amber van den AkkerDepartment for Health, University of Bath, Bath, UK. avda21@bath.ac.uk.ORCID 0000-0001-8365-3418
Xinmei SunDepartment of Linguistics and English Language, Lancaster University, Lancaster, UK.ORCID 0009-0001-3976-0686
Britta K MatthesDepartment for Health, University of Bath, Bath, UK.ORCID 0000-0003-2346-066X
Kathrin LauberSchool of Social and Political Science, University of Edinburgh, Edinburgh, UK.ORCID 0000-0003-0073-3004
Anna B GilmoreDepartment for Health, University of Bath, Bath, UK.ORCID 0000-0003-0281-1248

Funding

UK Research and Innovation MR/Y030753/1
6 · The paper itself

Abstract

backgroundMultistakeholderism as a norm stating that global public issues should be addressed by all those who affect or are affected by this issue, has become increasingly institutionalised in global governance, including the United Nations (UN) system. Despite an increasing body of evidence showing the risks of corporate capture of multistakeholder governance (MSG) and its related inability to deliver effective public health outcomes, this approach is increasingly common. While research shows that industry actors have pushed for MSG, and others have questioned its legitimacy, how MSG is constructed, legitimised and contested by different actors has not been systematically studied. Analysing responses to World Health Organization (WHO) consultations related to non-communicable diseases (NCDs) and associated risk factors, this study examines how actors construct or contest the legitimacy of MSG to address these public health issues.

resultsOur analysis of 135 responses to 10 consultations revealed significant differences in how actors justified or contested MSG. Proponents of MSG, primarily industry-affiliated organisations, often cited industry expertise and resources as key justifications for a multistakeholder approach, in which they invariably included industry as a key stakeholder. Conversely, non-profit and academic respondents often argued against industry inclusion in MSG, referring to conflicts of interest, corporate capture of the policy process and the associated risks that MSG with industry actors poses to democratic and effective policymaking. While actors commonly invoked the same values (e.g., participation, effectiveness, fairness), they interpreted these differently, to argue for or against the inclusion of industry in MSG.

conclusionOur findings underscore the contested nature of MSG, with actors calling on similar values and terminology to support fundamentally opposing positions. The ambiguity of concepts like participation, accountability and conflicts of interest may risk creating an opportunity for private sector interests to promote MSG as an ambiguous governance concept to fit their agenda. Given the normative role of WHO and other UN agencies in shaping what is considered 'good governance', it is essential for the WHO and other UN agencies to critically examine the evidence on multistakeholder approaches before deciding on its appropriateness and use unambiguous terminology when discussing their interpretation of the approach.

Indexed as

Global HealthIndustryReferral and ConsultationWorld Health OrganizationHumansNoncommunicable DiseasesQualitative ResearchCorporate captureGlobal governanceGlobal health policyMultistakeholder governance

Identifiers

PMID41219962
PMCPMC12606952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.